Glycemic control A combination of life style interaction and the use of drugs
|
|
- Stewart Henderson
- 6 years ago
- Views:
Transcription
1 Multifactorial management to reduce cardiovascular risk in patients with diabetes mellitus Glycemic control A combination of life style interaction and the use of drugs Eberhard Standl Munich Diabetes Research Institute at the Munich Helmholtz Center Master class in preventive cardiology Focus on diabetes and cardiovascular disease April 14, 2011 Geneva
2 UKPDS Landmark study in type 2 diabetes Patients studied n=5102
3 UKPDS: Clinical Outcomes after 10 years Life style plus drugs Intensive policy Conventional policy 7.0% HbA versus 1c 7.9% HbA 1c 12% 16% 25% 21% Any diabetes related endpoint Myocardial infarction Microvascular complications Retinopathy at 12 years Cardiovascular and all cause mortality P=0.029 P=0.052 P= P=0.015 NS UKPDS Group. Lancet 1998;352:
4 G Lowering Intensity & Diabetes Complications Trials in People with Dysglycemia and Type 2 Diabetes Yrs from Dx UKPDS (DCCT) ACCORD VADT ADVANCE Eye, Kidney, Nerve Disease CVD High IFG &/or IGT Type 2 Diabetes (T2DM) Dysglycemia
5 Glycemic control Meta-analysis of 5 prospective randomised trials (intensive vs standard) n= Mean HbA1c difference 0.9% Non-fatal MI (17% reduction) All cause mortality 0.83 ( ) 1.02 ( ) (Ray K et al. Lancet 2009;373:1765)
6 Issues beyond watch out for potential severe downsides, e.g. severe hypoglycemia and weight gain, especially in patients with preexisting CVD!
7 Intensive Glucose Lowering in Type 2 Diabetes ACCORD and ADVANCE HbA1c(%) HbA1c (%) Glycemia trial (n=10 251) HbA1c <6.0% vs HbA1c % Standard Severe hypoglycemia: 1.0 vs 3.1 %/yr Intensive Time of follow up (years) Glycemia trial (n=11 140) HbA1c 6.5% vs local guidelines Severe hypoglycemia: 0.4 vs 0.7 %/yr Standard Intensive (Gerstein et al. NEJM 2008;358:2545) (Patel et al. NEJM 2008;358: 2560) Time of follow up (months)
8 Hypoglycaemia requiring third-party assistance Standard Intensive Stand Inten Stand Inten HbA1c % Hypo %/yr UKPDS Newly diagnosed SU Ins PROactive High SV risk <0.25 ADOPT Recently diagnosed <0.2 Steno microalbu ~1 ~1 4T No ins, >1yr diagnosed ACCORD Older high CV risk ADVANCE Older high CV risk VADT Older high CV risk ~1.6 ~ 4?
9 Differences between the ACCORD and ADVANCE studies Characteristic ACCORD ADVANCE Baseline N 10,251 11,140 Mean age (Y) Duration of diabetes (Y) 10 8 Median HbA1c at baseline History of macrovascular disease (%) Intervention Target HbA1c (%) < Median duration (Y) Medical treatment at study completion (intensive vs standard) (%) Insulin 77 vs vs 24 Metformin 95 vs vs 67 Secretagoue (sulphonylurea or glinide) 87 vs vs 62 Thiazolidinedione 92 vs vs 11 use of Acarbose in 19% Dluhy et al. N Engl J Med 2008;358:2630-3
10 ACCORD Adjusted cause of death in relation to treatment strategy and by occurrence of hypoglycemia Standard participants Intensive participants No hypo event n=4.832 At least one severe hypo n=175 No hypo event n=4.290 At least one severe hypo n=528 All cause mortality 4% 10% 5% 6% CVD death 2% 5% 2% 4% Cancer death 1% 2% 1% 1% Non CVD/ Non cancer death Unable to classify 1% <1% 1% 1% 1% 1% <1% <1% Bonds DE et al. BMJ 2010: 340:b4909 doi: /bmj.b4909
11 Risk of Death over a Range of Average HbA1c Adjusted log (Hazard Ratio) by Treatment Strategy Relative to Standard at HbA1c of 6% Steady increase of risk from 6 to 9% HbA1c with intensive strategy Intensive strategy Standard strategy Calles-Escandon et al NEJM 2010 HR for 1% higher average HbA1c Intensive Strategy: 1.66 Standard Strategy: 1.14 Raising A1c to 7.2 % in the intensive group did not reduce excess mortality NEJM 2011; 364: Average HbA1c % Excess risk with intensive strategy vs standard occurred above HbA1c 7% Riddle M et al. ADA Congress, New Orleans June 2009
12 Primary outcome subgroup analyses Subgroup Patient Events no no (Gerstein et al. NEJM 2008;358:2545)
13 UKPDS 30 y Follow-up: Reduction of diabetes-related endpoints and myocardial infarction Holman R et al. New Engl J Med 2008;359, epub 10 September 2008
14 Guidelines recommend target HbA 1c as near to normal as safely possible 1 ADA. Diabetes Care 2007; 30 (Suppl. 1):S4 S41. 2 ACE/AACE Diabetes Road Map Task Force, Available at: 3 IDF Clinical Guidelines Taskforce, Available at: 4 CDA. Can J Diabetes 2003; 27 (Suppl. 2):S1 S NICE, Available at: 6 ALAD. Rev Asoc Lat Diab 2000; 8 (Suppl. 1): Asian-Pacific Type 2 Diabetes Policy Group, Available at: 8 NSW Health Department, 1996.
15 The AACE recommendations on glycaemic control No problem even to normalize glycemia, provided it can be achieved without side effects Near-normal targets (without hypoglycaemia) are advocated: HbA1c 6.5% Fasting plasma glucose <110 mg/dl 2-h post-prandial glucose <140 mg/dl Post-prandial hyperglycaemia is linked to macrovascular disease Effective management of post-prandial glucose can reduce this burden AACE Diabetes Mellitus Clinical Proactice Guidelines Task Force. Endocrine Practice vol 13 (Suppl 1); May/June 2007.
16 A HbA1c of 7 % is a reasonable deal: It can be attained by the patient by the doctor Needs less intensive polypharmacy (less costs) Reduces microvascular complications Reduces macrovascular complications (legacy effect) Further aggressive HbA1c reduction may increase the risk of side effects, e.g. weight gain, hypoglycemia, even cardiovascular mortality Conversely, the further gain of further HbA1c lowering is rather little (NNT 30 to 50) and only proven for (functional) renal parameters (e.g. microalbuminuria), not for macrovascular outcomes
17 Blood glucose patterns with progressive Type 2 Diabetes Breakfast 15 Postabsorptive (Night phase) Postprandial (Day phase) HbA 1c -Value ,5 9 % ,0 8 8,9 % Morning phase L. Monnier et al. Diabetes Care ,4 4,4 0,7 7 7,9 % 6,5 6,9 % < 6,5 % Duration of Diabetes mellitus (in years) )
18 New ESC/EASD Guidelines Suggested policy for the selection of glucoselowering therapy according to the glucometabolic situation ESC Pocket Guidelines adapted from European Heart Journal (2007) 28, GUIDELINES ON DIABETES, PRE-DIABETES AND CARDIOVASCULAR DISEASES,DPP4-I, GLP1-A.,DPP4-I, GLP1-A.
19 Mean efficacy of pharmacotherapeutic options in Type 2 diabetes* Drug Option Mean HbA 1c Lowering Capacity (%) Incretin enhancers (DPP-IV-inhibitors) GLP-1 analogues 1.0 -Glucosidase inhibitors Biguanides Glitazones (TZDs) Sulfonylureas (and analogues) Insulins CB-1 receptor antagonist 0.7 * Treatment effects vary with treatment dose and patient characteristics. CB-1=cannabinoid Type 1. DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1. DeFronzo RA. Ann Intern Med. 1999;131: Nathan DM. N Engl J Med. 2002;347: Todd JF, Bloom SR. Diabet Med. 2007;24: Scheen AJ. Best Pract Res Clin Endocrinol Metab. 2007;21: Vinik A. Clin Ther. 2007;29 Spec No:
20 Early combination strategy in blood glucose lowering therapy additive efficacy through different mode of actions therapy of different abnormalities at medium dose 70-80% of maximum effect less side effects α-glucosidase inhibitors Incretin enhancers/glp1-ag. Sulfonylureas und Analogs Glitazones Metformin
21 Guideline Recommendations: Drug Combinations with Different Mechanisms 2007 AACE Guidelines Combination therapy with different mechanisms antihyperglycemic drugs is more beneficial 2009 ADA /EASD Consensus combination of anti-hyperglycemic drugs with different mechanisms can achieve the maximum synergy
22 Target-driven strategy for sustained glycaemic control HbA 1C (%) Monotherapy Insulin +/- oral agents Diet +Combinations of oral agents ULN Failure-based treatment of symptoms approach HbA 1C < 7% approach Diagnosis +5 yrs +10 yrs + 15 years Campbell IW. Br J Cardiol 2000;7:625-31
23 Options of insulin therapy in type 2 diabetes fasting hyperglycemia: long acting insulin (or analogue) at bedtime postprandial hyperglycemia: prandial insulin therapy with rapid acting insulin analogues or regular insulin constant hyperglycemia: pre-mixed insulin (50/50 to 25/75) before breakfast and supper, respectively NB! All options may by combined with oral agents: e.g. Metformin!
24 4TStudy: Results over 3 Years incl. Hypoglycaemia Mean±1SD N Engl J Med 2009;361:
25 Adverse Events Biphasic N=235 Prandial N=239 Basal N=234 p value Any serious event 105 (44.7%) 79 (33.1%) 78 (33.3%) Death from any cause 7 (3.0%) 9 (3.8%) 4 (1.7%) 0.23 Cardiovascular death 4 (1.7%) 9 (3.8%) 1 (0.4%) Any adverse event 228 (97.0%) 235 (98.3%) 227 (97.0%) 0.58 No significant differences were seen between groups in: Serious adverse events occurring in more than 1% in any group Non-serious adverse events occurring in more than 10% in any group N Engl J Med 2009;361:
26 New ESC/EASD Guidelines Potential downsides of pharmacological treatment modalities in patients with type 2 diabetes ESC Pocket Guidelines adapted from European Heart Journal (2007) 28, GUIDELINES ON DIABETES, PRE-DIABETES AND CARDIOVASCULAR DISEASES, GLP1-A, DPP4-Inhibitors, DPP4-Inhibitors
27 Look AHEAD Trial: 1 year follow-up Look AHEAD research group. Diabetes Care 2007;30:
28 Look AHEAD trial: changes of glycaemic and blood pressure control after 1 year Measure Intensive lifestyle intervention N Use of diabetes medications (%) Baseline Year 1 Change 86.3± ± ±0.6 Diabetes support and education 86.5± ± ±0.5 P 0.93 <0.001 <0.001 Fasting glucose (mg/dl) Baseline Year 1 Change 151.9± ± ± ± ± ± <0.001 <0.001 HbA1c (%) Baseline Year 1 Change 7.25± ± ± ± ± ± <0.001 <0.001 Use of antihypertensives (%) Baseline Year 1 Change 75.3± ± ± ± ± ± SBP (mmhg) Baseline Year 1 Change 128.2± ± ± ± ± ± <0.001 <0.001 DBP (mmhg) Baseline Year 1 Change 69.9± ± ± ± ± ± <0.001 <0.001 Look AHEAD research group. Diabetes Care 2007;30:
29 New ESC/EASD Guidelines Recommended treatment targets for patients with diabetes and CAD (2) ESC Pocket Guidelines adapted from European Heart Journal (2007) 28, GUIDELINES ON DIABETES, PRE-DIABETES AND CARDIOVASCULAR DISEASES
30 T2D n = year follow up HbA1c baseline: 7.6% Diabetes duration: 7.6 years Advice for physical activity: moderate, aerobic endurance training (30-60% of max. HF), aim: > 10 MET/ h /wk) 7 visits, total of ca 2 h counselling, 1 visit every 3 Month Di Loreto et al, Diabetes Care, 2005
31 Effects of physical activity in T2D Walking / Hours / Week* 0 1,5 4 5,5* 7,5 12 Weight (kg) + 0,8 + 0,6 + 0,1-2,2-3,0-3,2 Waist (cm) + 1,0 + 1,0-0,9-3,8-5,5-7,1 HbA 1c (%) + 0,03-0,06-0,44-0,8-1,11-1,19 BD syst. (mmhg) - 1,8-1,5-6,4-5,5-6,6-9,2 BD diast. (mmhg) - 4,6-2,4-2,9-4,8-5,3-7,1 Chol. (mg/dl) - 3,8-5,6-10,2-10,7-7,4-10,9 LDL-Chol. (mg/dl) - 4,5-7,1-3,4-5,3-6,3-7,7 HDL-Chol. (mg/dl) + 0,1 + 1,1 + 2,9 + 5,6 + 10,4 + 6,3 Triglycer. (mg/dl) + 3,4 + 2,1-48,2-55,2-57,4-68,4 CAD Risk (%) + 0,1-0,3-2,6-3,7-4,8-4,3 * e.g MET: 45 min walking (4 mph) /day, ca. 5 km/day) p <0,05 Di Loreto C. et al. Diabetes Care (2005)28:
32 - 593 $ drug costs Effects of physical activity in T2D Walking / Hours / Week* 0 1,5 4 5,5* 7,5 12 Weight (kg) + 0,8 + 0,6 + 0,1-2,2-3,0-3,2 Waist (cm) + 1,0 + 1,0-0,9-3,8-5,5-7,1 HbA 1c (%) + 0,03-0,06-0,44-0,8-1,11-1,19 BD syst. (mmhg) - 1,8-1,5-6,4-5,5-6,6-9,2 BD diast. (mmhg) - 4,6-2,4-2,9-4,8-5,3-7,1 Chol. (mg/dl) - 3,8-5,6-10,2-10,7-7,4-10,9 LDL-Chol. (mg/dl) - 4,5-7,1-3,4-5,3-6,3-7,7 HDL-Chol. (mg/dl) + 0,1 + 1,1 + 2,9 + 5,6 + 10,4 + 6,3 Triglycer. (mg/dl) + 3,4 + 2,1-48,2-55,2-57,4-68,4 CAD Risk (%) + 0,1-0,3-2,6-3,7-4,8-4,3 * e.g MET: 45 min walking (4 mph) /day, ca. 5 km/day) p <0,05 Di Loreto C. et al. Diabetes Care (2005)28:
33 ADA and EASD consensus 1. Well-validated core therapies At diagnosis: Lifestyle + Metformin Lifestyle + Metformin + Basal insulin Lifestyle + Metformin + Sulfonylurea Lifestyle + Metformin + Intensive insulin STEP 3 STEP 1 STEP 2 2. Less wellvalidated therapies Lifestyle + Metformin + Pioglitazone Lifestyle + Metformin + GLP-1 agonist Lifestyle + Metformin + Pioglitazone + Sulfonylurea Lifestyle + Metformin + Basal insulin (Nathan et al. Diabetes Care 2009;32:193)
34 The New IDF Therapeutic Algorithm (still under review) Lifestyle measures = usual approach Then, at each step, if not to target (generally HbA 1c <7.0 %) Consider first line Metformin Sulfonylurea or α-glucosidase inhibitor = alternatives as per Guideline Consider second line Sulfonylurea Metformin (if not first line) or Thiazolidinedione, or DPP-4 inhibitor, or α-glucosidase inhibitor Consider third line Basal insulin, or Pre-mix insulin or Thiazolidinedione, or DPP-4 inhibitor, or α-glucosidase inhibitor GLP-1 mimetic Consider fourth line Basal + meal-time insulin Basal insulin, or Pre-mix insulin (later basal+meal-time)
35 Present approach to diabetes management in type 2 diabetic patients Consult endocrinologist / diabetologist for Structured education Blood glucose self-monitoring (also post-prandial glucose) Appropriate nutrition counselling Pharmacotherapy discussing pros and cons Benefits Caveats Insulin Yes Heart? Metformin Yes Impaired kidney function Sulfonylureas Yes Cardiac K-channels? α-glucosidase-inhibitors Yes Glitazones Yes(pio)/? CHF (CHD rosiglitazone?) Glinides No (NAVIGATOR) Incretin-based agents? CHF=congestive heart failure CHD=coronary heart disease
36 Beyond HbA1c targets after ADVANCE/VADT/ACCORD/UKPDS 2011 No change of targets (<7% or <6.5%), in particular in view of the prevention of microvascular (and most likely also cardiovascular) complications but Go slow, especially in patients with high baseline HbA1c values and pre-existing CV disease Avoid hypoglycaemia and weight gain Early treatment and perhaps prevention appears to give the best results Some pharmacotherapies (e.g. insulin, rosiglitazone, SUs) cannot be excluded as a culprit in patients with cardiovascular disease The beneficial effects of improved blood glucose therapy on cardiovascular disease do emerge longer term and there is a legacy effect (metabolic memory) Weight neutral, nonhypoglycemic options (e.g. metformin, acarbose, DPP4-inhibitors) appear to be preferable
37 1. Lifestyle intervention (healthy eating, weight control, physical activity) 2. Metformin (glycaemic control, reduced CV events) No hypoglycaemia, no weight gain 3. Second (oral) agent (glycaemic control) SU Glinide TZD -Gluc. Inh. DPP-4 Inh. Incretin Mimetic Insulin (basal) Cheap Hypo BW Rapid acting Costs Hypo BW ø Hypo Costs BW CV safety CV Ev.? ø Hypo Weak GI-AE ø Hypo ø BW No AE ß-cell health? ø Hypo BW ß-cell health? Nausea etc. Always works Hypo BW Nauck 2008
38 WHO
39 Hyperglycaemia is common and often undiagnosed in patients with CAD in Europe and Asia Euro Heart Survey 1 (n=4,961) China Heart Survey 2 (n=3,513) 31% 29% 33% 23% 12% 3% 21% 25% 2/3 of patients have hyperglycaemia 20% 24% ~3/4 of patients have hyperglycaemia Normal glucose tolerance Prediabetes (IFG) Prediabetes (IGT) CAD: coronary artery disease; OGTT: oral glucose tolerance test; FPG: fasting plasma glucose; IFG: impaired fasting glucose; IGT: impaired glucose tolerance 1. Bartnik M, et al. Eur Heart J 2004;25: Hu DY, et al. Eur Heart J 2006;27: Newly diagnosed diabetes Previously known diabetes
40 Euro Heart Survey: Improved cardiovascular outcomes in patients with newly detected diabetes and implementation of diabetes pharmacotherapy Anselmino, Malmberg, Standl, Rydén, EuroHeartJ, (2008) 29: Prof. Eberhard Standl 44
41 Mortality trends in subjects with and without diabetes during 33 years of follow-up CVD CVD CHD CHD Jansson SPO et al, Diabetes Care 2010; 33:
42 Guidelines of the European Society of Cardiology (Euro Heart J: 2007; 28: ) The first Joint ESC/EASD Guidelines in Cardio-Diabetology : A perspective in reducing CV risk L. Ryden & E.Standl Co-chairs
43 Multifactorial intervention in type 2 diabetes The Steno 2 study Composite endpoint CV-death, MI or stroke, CABG or PCI, limb amputation or vascular surgery (Gaede et al N Engl J Med 2008;358:580-91) European guidelines: diabetes and cardiovascular disease
44 Steno 2 Study 13 year follow up: negative trends in weight management may have challenged the benefits of blood glucose lowering therapy (Gaede et al N Engl J Med 2008;358:580-91)
45 Ten important recommendations (1) To reach (all) treatment targets including those for glycaemic control To screen for DM and IGT by means of an OGTT in all patients with coronary artery disease and in other high risk individuals To let life style counselling be the cornerstone in preventing DM and CVD To offer patients with DM and ACS standard guideline based treatment, early angiography and mechanical revascularisation To apply strict, when needed insulin based, glucose control in acutely ill DM patients Europ Heart J 2007; 28:
46 Ten important recommendations (2) To favour CABG over PCI when revascularising DM patients To use drug-eluting stents in PCI with stent implantation To include investigations for cardiac autonomic dysfunction, heart failure, arrhythmias, hypotension, PVD (Doppler-Index), GFR and (micro) - albuminuria To use a multifactorial (tight glucose, BP and lipid-control and antiplatelet therapy) approach To establish a collaboration between cardiologists and diabetologists Europ Heart J 2007; 28:
47 Variable Lifestyle modification Smoking cessation BP ESC/EASD Guidelines Treatment targets of multifactorial therapy Target Structured education Obligatory <130 / 80 mm Hg Renal dysf <125/75 HbA1c (DCCT standard) 6.5% mmol/l mg/dl Venous plasma glucose < Cholesterol < LDL < HDL male >1.0; female >1.2 40; 46 Triglycerides <
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationMaster class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April
Master class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April 14 2011 Introduction Course objectives A review of available guidelines Lars Rydén Cardiology Unit Department
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More information효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과
효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 (2011.10.30.) 가천의대길병원내분비대사내과 박이병 내용 배경 경구혈당강하제의병합이왜필요한가? (WHY?) 경구혈당강하제의병합은언제시작하나? (WHEN?) 경구혈당강하제의병합은어떻게하는것이좋은가?(HOW) 맺음말 배경 : drugs for treating diabetes In 1995 :
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationDiabetes Mellitus: Overview and Guidelines
Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationMaster Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden
Master Class in Preventive Cardiology The New MI Phenotype OR Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden The New MI Phenotype OR Coronary disease and glucose abnormalities Klas
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationBlood glucose variations and cardiovascular risk in patients with diabetes
Blood glucose variations and cardiovascular risk in patients with diabetes Thessaloniki 13 November 2009 Oliver Schnell, Executive Member of the Managing Board Diabetes Research Institute, Munich UKPDS
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationPhilippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus
Philippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus Iris Thiele Isip Tan MD, MSc, FPCP, FPSEM Chief, Medical Informatics Unit Associate Professor IV, UP College of
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationDIABETES IN 2007 What snew
DIABETES IN 2007 What snew 1 Objectives 1. Review recently published clinical trials in diabetes What does this mean to us? 1. Discuss novel concepts in the treatment of diabetes What should we expect?
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDiabetes for GP CME 2009
Diabetes for GP CME 2009 The good, the bad and the ugly Dr Paul Drury Medical and Clinical Director, Auckland Diabetes Centre Some of the areas to cover New NZ data on epidemiology New trials: ACCORD,
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More information